NSNodoka Sakurai

Nodoka Sakurai

*This is an algorithmically generated author record based on publicly available information.

Nodoka Sakurai has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Invasive Pulmonary Aspergillosis in a Previously Healthy Child With Primary Epstein–Barr Virus Infection

    by Hikaru Takahashi, Kenji Kondo, Mayu Hachiya, Yukiko Higashide, Jun Kunizaki, Emiko Hoshino, Nodoka Sakurai, Toshihiko Mori

    Invasive pulmonary aspergillosis (IPA) rarely occurs in previously healthy children. We report a case of IPA complicating primary Epstein–Barr virus (EBV) infection in a previously healthy 5-year-old Japanese boy. During acute EBV infection, he developed persistent fever, systemic inflammation, as reflected by elevated serum LDH (lactate dehydrogenase) and ferritin levels, and profound neutropenia (absolute neutrophil count 10 d), and received systemic corticosteroids. Persistent fever prompted further evaluation, and chest computed tomography showed multiple bilateral pulmonary nodules with halo signs. Positive serum galactomannan antigen supported a clinical diagnosis of IPA. Voriconazole therapy led to clinical and radiologic resolution. Comprehensive immunologic evaluation revealed no evidence of primary immunodeficiency. This case suggests that primary EBV infection, particularly when complicated by severe neutropenia and corticosteroid exposure, may cause transient immunosuppression sufficient to predispose otherwise healthy children to IPA. Early recognition and prompt antifungal treatment may improve outcomes.

  • A Study of 28 Pediatric Patients With Drug Crystals Following Tosufloxacin Administration

    by Toshihiko Mori, Mayu Hachiya, Hikaru Takahashi, Yukiko Higashide, Jun Kunizaki, Emiko Hoshino, Nodoka Sakurai, Nami Tosaoka, Yasunari Takakuwa, Azusa Kawaguchi, et al.

    Background: Tosufloxacin (TFLX) is an oral fluoroquinolone antibiotic that has been reported to cause crystalluria and acute kidney injury. To clarify the clinical course of drug crystals after TFLX administration in children, we conducted a retrospective review of pediatric patients who developed drug crystals after receiving TFLX. Methods: This retrospective study included 28 pediatric patients aged 15 years or younger who were treated in the Department of Pediatrics at NTT Medical Center Sapporo, Japan, between January 1, 2016, and March 31, 2026, and in whom drug crystals were detected in urine sediment after TFLX administration. Results: The median age of the patients at diagnosis was 6.5 years (interquartile range: 4.4 to 8.2 y), and 11 patients (39%) were male. The median time to diagnosis after TFLX administration was 2 days (interquartile range: 1 to 3 d). Gastrointestinal symptoms, such as vomiting and abdominal pain, were observed in 6 patients (21%), and decreased appetite was observed in 3 patients (11%). All patients who had a known dosage received an appropriate dose of TFLX. Ten patients (36%) were diagnosed with acute kidney injury, and they improved within 3 to 5 days after discontinuing TFLX and replacing fluids. Conclusions: Despite the administration of the appropriate TFLX dosage, drug crystals were observed in the urine sediment 1 to 4 days after administration. When administering TFLX, it is important to be aware that drug crystals and acute kidney injury may occur. Discontinuing the drug can prevent progression of kidney injury.